Additionally, combination treatment resulted in a dose-dependent reduction in cell viability in all HNSCC cell lines tested, which was enhanced in the presence of TNFα (Figure 1E and Supplementary Figure S1D). This evidence concerns the gene TNF and head and neck squamous cell carcinoma.